Contrasting Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)

Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Insider & Institutional Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Gyre Therapeutics and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Traws Pharma	N/A	-23,868.92%	-165.52%

Valuation and Earnings

This table compares Gyre Therapeutics and Traws Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	6.80	$5.03 million	($0.21)	-33.86
Traws Pharma	$2.79 million	3.13	$9.17 million	($1.74)	-0.33

Traws Pharma has lower revenue, but higher earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Gyre Therapeutics and Traws Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	1	0	1.67
Traws Pharma	1	4	0	0	1.80

Gyre Therapeutics presently has a consensus price target of $16.00, suggesting a potential upside of 125.04%. Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 75.90%. Given Gyre Therapeutics’ higher probable upside, research analysts clearly believe Gyre Therapeutics is more favorable than Traws Pharma.

Summary

Gyre Therapeutics beats Traws Pharma on 10 of the 14 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.